Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elio Aarón Reyes‐Espinoza"'
Autor:
Jesús Alonso Gándara-Mireles, Ismael Lares-Asseff, Elio Aarón Reyes Espinoza, Javier G. Blanco, Isaias Chairez Hernández, Lourdes Patricia Córdova Hurtado, Verónica Loera Castañeda, Leslie Patrón Romero, Cristina Venzor Sánchez, Hugo Payan Gándara, Dinora Arechiga Gurrola, Horacio Almanza Reyes
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Background: The identification of genetic risk factors for Acute Lymphoblastic Leukemia (ALL), are increasingly urgent and necessary.Objective: The purpose of this study is to determine the association of the genetic polymorphisms ABCC1 rs3743527, NC
Externí odkaz:
https://doaj.org/article/538c5729e52c42b48f8d6e613df6f88b
Autor:
Jesús Alonso Gándara-Mireles, Ismael Lares-Asseff, Elio Aarón Reyes Espinoza, Ignacio Villanueva Fierro, Verónica Loera Castañeda, Lourdes Patricia Cordova Hurtado, Carla Díaz González, Leslie Patrón Romero, Horacio Almanza Reyes
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
Purpose Doxorubicin is an important antineoplastic agent with wide interindividual variability in response to treatment and in its cardiotoxic effects. To determine the effect of genotypic status of three single-nucleotide variants in ABCC1, NCF4, an
Autor:
Jesús Alonso Gándara-Mireles, Horacio Almanza Reyes, Leslie Patrón Romero, Ignacio Villanueva Fierro, Elio Aarón Reyes Espinoza, Verónica Loera Castañeda, Javier G. Blanco, Antonio Emilio González Font, Lourdes Patricia Córdova Hurtado, Ismael Lares-Asseff
Publikováno v:
Pharmacogenetics and Genomics. 31:108-115
Objectives Cardiotoxicity is a frequent complication secondary to the use of anthracyclines for cancer chemotherapy. Evidence suggests that certain polymorphic genetic variants modify the risk for anthracycline-related cardiotoxicity. Reports documen
Autor:
Berenice Sánchez-Jara, Gerardo González-Martínez, Cecilia Rodríguez‐Castillejos, Jaime García-Chávez, Irving Armando Domínguez‐Varela, Edna Liliana Tamez-Gómez, Nuria Citlali Luna‐Silva, Mirna Guadalupe Ríos‐Osuna, Natalia Elizabeth Padilla‐Durón, Ricardo De León‐Figueroa, Aida Mashenka Moreno‐González, Janet Soto‐Padilla, Claudia Sofia Gómez‐González, Ana Itamar González-Ávila, Adela López‐Miranda, Jorge Nemi‐Cueto, Maria Mora-Torres, Eric Israel Gutiérrez‐Juárez, Laura Villarreal-Martínez, Rogelio Paredes‐Aguilera, Elio Aarón Reyes‐Espinoza, Karla Maldonado‐Silva, Héctor Manuel Tiznado-García, Elias Adán Godoy‐Salinas, Efraín Aquino-Fernández
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 26(2)
INTRODUCTION Development of inhibitors is the most serious complication in patients with haemophilia (PWH). The prevalence of inhibitors in patients with severe haemophilia A (HA) is approximately 25%-30%. Inhibitor prevalence differs among populatio
Autor:
José-Manuel Salas-Pacheco, Isaias Chairez Hernández, Ossyneidee Gutiérrez-Álvarez, Elio-Aarón Reyes-Espinoza, Horacio Almanza-Reyes, Ismael Lares-Asseff, Claudia E. Bailón-Soto, Carlos Galaviz-Hernández, Martha Sosa-Macías
Publikováno v:
Drug Metabolism and Personalized Therapy. 31
Background Folate metabolism plays an essential role in the processes of DNA synthesis and methylation. Deviations in the folate flux resulting from single-nucleotide polymorphisms in genes encoding folate-dependent enzymes may affect the susceptibil